Who are LY2216684's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Latuda©, Latuda (Lurasidone), MM120 (LSD D-Tartrate), Lurasidone 20, 40, 60, 80 mg, flexibly dosed, NMRA-335140, NRX-101 Oral Capsule.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ly2216684.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

LY2216684 — Competitive Intelligence Brief

LY2216684 (LY2216684) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT7 receptor antagonist. Area: Psychiatry/Neurology.

phase 3 5-HT7 receptor antagonist 5-HT7 receptor Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

LY2216684 (LY2216684) — Eli Lilly and Company. LY2216684 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LY2216684 TARGET	LY2216684	Eli Lilly and Company	phase 3	5-HT7 receptor antagonist	5-HT7 receptor
Latuda©	Latuda©	University of North Carolina, Chapel Hill	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT7 receptor, serotonin 5-HT1A receptor
Latuda (Lurasidone)	Latuda (Lurasidone)	Massachusetts General Hospital	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT7 receptor
MM120 (LSD D-Tartrate)	MM120 (LSD D-Tartrate)	Definium Therapeutics US, Inc.	phase 3	Serotonergic psychedelic / 5-HT agonist	5-HT1A, 5-HT2A, 5-HT7 receptors
Lurasidone 20, 40, 60, 80 mg, flexibly dosed	Lurasidone 20, 40, 60, 80 mg, flexibly dosed	Sumitomo Pharma America, Inc.	phase 3	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT7 receptor
NMRA-335140	NMRA-335140	Neumora Therapeutics, Inc.	phase 3	5-HT7 receptor antagonist	5-HT7 receptor
NRX-101 Oral Capsule	NRX-101 Oral Capsule	NeuroRx, Inc.	phase 3	Fixed-dose combination (NMDA receptor modulator + atypical antipsychotic)	NMDA receptor (d-cycloserine component); dopamine D2 receptor and serotonin 5-HT7 receptor (lurasidone component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT7 receptor antagonist class)

Otsuka Pharmaceutical Development & Commercialization, Inc. · 2 drugs in this class
Dr. Reddy's Laboratories Limited · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Neumora Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LY2216684 — Competitive Intelligence Brief. https://druglandscape.com/ci/ly2216684. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab